Immunome (IMNM) Free Cash Flow Growth (1y) (2020 - 2026)

Immunome (IMNM) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 7.12%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1,092.51%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 66.37%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.98%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Immunome 2.59 Bn 2.00 Bn - -8.67%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.67%
Dec 31, 2025 -20.30%
Sep 30, 2025 -25.77%
Jun 30, 2025 -72.18%
Mar 31, 2025 -382.15%
Dec 31, 2024 -146.55%
Sep 30, 2024 -320.91%
Jun 30, 2024 -363.61%
Mar 31, 2024 -149.12%
Dec 31, 2023 -159.30%
Sep 30, 2023 -12.05%
Jun 30, 2023 28.42%
Mar 31, 2023 475.27%
Dec 31, 2022 1.85%
Sep 30, 2022 -82.87%
Jun 30, 2022 -121.42%
Mar 31, 2022 -78.97%
Dec 31, 2021 -12.67%
Sep 30, 2021 -56.11%
Jun 30, 2021 -101.90%